DEXCOM INC — Director's Dealing 2020

Mar 25, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2020-03-13

Reporting Person: DOUBLEDAY RICHARD (EVP Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-13	Common Stock	G	523	$0.0	Disposed	51482	Direct
2020-03-23	Common Stock	S	231	$207.7086	Disposed	10483	Indirect
2020-03-23	Common Stock	S	1300	$209.55	Disposed	9183	Indirect

Footnotes

F1: The transaction represents a gift by the Reporting Person of 523 shares to a charitable donor advised fund.

F2: Included in this number are 35,492 unvested restricted stock units, 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 10,910 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021.

F3: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F4: This transaction was executed in multiple trades at prices ranging from $207.28 to $208.12. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F5: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.